SYRS, US87184Q2066

Syros Pharmaceuticals stock trades at USD 0.0004 after delisting

Published on 10/04/2026 at 10:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

A February 28, 2025 board decision preceded the company wind-down. Historical FY2023 revenue was USD 9.9 million versus USD 2.0 million in FY2019.

SYRS, US87184Q2066, Illustration mit AI erstellt.

Syros Pharmaceuticals stock (ISIN US87184Q2066) stood at USD 0.0004 on OTC Markets on September 11, 2026. The quote carried a 0.00 percent daily change and volume of 62,234 shares, while the company's corporate status remains defined by a wind-down approved after its lead clinical setback.

Nasdaq delisting changed the story

According to EdgeChat, Syros's board approved voluntary Nasdaq delisting on February 28, 2025, with a Form 25 planned for March 10, 2025. The same account describes a creditor-approved wind-down after the SELECT-MDS-1 Phase 3 trial failed to meet its primary endpoint.

The company still describes its mission as developing treatments for hematologic malignancies on its investor-relations page, including work involving small molecules that control gene expression. Syros Pharmaceuticals also identifies Computershare Trust Company as its transfer agent.

Historical revenue rose before the wind-down

Historical figures published by Fair Value Calculator show fiscal year 2023 revenue of USD 9.9 million, compared with USD 2.0 million in fiscal year 2019. The same source reports a fiscal year 2023 net loss of USD 165 million, placing the revenue increase alongside substantial historical losses.

That comparison matters because the stock now trades in an OTC setting rather than the Nasdaq market where Syros was listed from 2016. The company profile also identifies biotechnology as its industry and hematologic malignancies as the central therapeutic area.

OTC quote remains highly compressed

On September 11, 2026, Syros Pharmaceuticals stock stood at USD 0.0004 on OTC Markets, with a 0.00 percent daily change and 62,234 shares traded. The price and volume snapshot underlines how differently the security now trades from its earlier Nasdaq period.